Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/125,372external-prioritypatent/US5431920A/en
Application filed by Simon R. Bechard, Merck Frosst Canada Inc., Merck Frosst Canada Incorporated, Merck Frosst Canada & Co./Merck Frosst Canada & Cie, Merck Frosst Canada Ltd.filedCriticalSimon R. Bechard
Publication of CA2170537A1publicationCriticalpatent/CA2170537A1/en
Application grantedgrantedCritical
Publication of CA2170537CpublicationCriticalpatent/CA2170537C/en
The present invention relates to a novel oral dosage form of a bisphosphonic active ingredient for use in treatment of diseases involving bone resorption and formulated in an enteric-coated form for administration to subjects exhibiting upper gastrointestinal tract sensivity to bisphosphonic acid compounds.